Horizon Pharma Announces Receipt Of Two Additional U.S. Patent Allowances For DUEXIS®

NSAID‐containing medications like DUEXIS can cause high blood pressure or make existing high blood pressure worse, either of which can increase the chance of a heart attack or stroke.  Your health care provider should check your blood pressure while you are taking DUEXIS.

Before you start taking DUEXIS, tell your health care provider if you have heart problems, kidney problems, or liver problems, or if you are taking medications for high blood pressure.  DUEXIS can increase the chance of potentially significant liver injury and/or kidney injury, which may be fatal. Stop taking DUEXIS immediately and contact your health care provider if you experience any signs and/or symptoms of liver or kidney injury.

Serious allergic reactions, including skin reactions, can happen without warning and can be life threatening.  Stop taking DUEXIS and consult your doctor immediately if you get a skin rash or if you start to have problems breathing or swallowing or if you develop swelling of your face or throat.

The most common side effects of DUEXIS include nausea, diarrhea, constipation, upper abdominal pain and headache.

Please see Medication Guide and full Prescribing Information.

About Horizon PharmaHorizon Pharma, Inc. is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. For more information, please visit www.horizonpharma.com.

Forward-Looking StatementsThis press release contains forward-looking statements, including statements regarding the issuance of patents based on the notices of allowance from the U.S. Patent and Trademark Office and the ability to protect the commercial potential of DUEXIS to 2028.  These forward-looking statements are based on management's expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include risks regarding whether the administrative processes required for the issuance of patents as indicated in the notices of allowance will be completed in a timely matter or at all, whether the patents, if issued as indicated in the notices of allowance, will provide sufficient protection and market exclusivity for DUEXIS, whether any patents issued to Horizon may be challenged, invalidated, infringed or circumvented by third parties and other factors described in Horizon's filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in those filings.  Forward-looking statements speak only as of the date of this press release, and Horizon undertakes no obligation to update or revise these statements, except as may be required by law.

Contacts Robert J. De VaereExecutive Vice President, Chief Financial Officer [e-mail]

Media Geoff CurtisDJE Science312-550-8138 [e-mail]

Investors Kathy GalanteBurns McClellan, Inc.212-213-0006 [e-mail]

 

« First ‹ Previous 1 2 3 Next › Last »